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Abstract

Objective: To determine whether ultrafiltration can be used as primary treatment of
Congestive Heart Failure.
Study Design: Review of three English language, non-blinded randomized controlled
trials from 2005, 2007 and 2008.
Data Sources: Randomized, controlled, non-blinded clinical trials comparing
ultrafiltration to intravenous diuretics found using Ovid Medline and PubMed databases.
Outcome measured: Weight loss after 48 hours was measured at discharge, and at days
10, 30, and 90 post-discharge. Dyspnea after 48 hours was measured as a perception of
the patient on a scale from 1 to 7, 1 being markedly worse, 7 being marked improvement.
Net fluid loss after 48 hours was measured as ultrafiltrated in the ultrafiltration group and
as urine output in the intravenous diuretic and usual care groups. Finally,
rehospitalizations for heart failure-related issues was measured, starting on the day of
discharge through 90 days post-discharge.
Results: There were statistically significant results for weight loss during hospitalization,
and the p-value for rehospitalization for symptoms of heart failure 90 days post-treatment
was < 0.05. Net fluid loss over 48 hours was didn’t prove to be significant. Hypotension
was the most frequent adverse event reported, but was not reported consistently
throughout all three studies; one study didn’t report adverse events at all.
Conclusions: The studies have proven ultrafiltration to be a safe alternative to intravenous
diuretics for the treatment of congestive heart failure but there is not enough consistent,
significant data to say that it can be used as initial primary treatment. Further studies with
larger and more specific sample populations need to be done in order to better prove true
long-term efficacy and cost-effectiveness.
Key Words: Ultrafiltration, CHF, Heart Failure
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Introduction:
Congestive Heart Failure is a growing health concern for the aging and elderly
population in the United States. Heart Failure is the mechanical failure of the heart and
occurs when it is no longer able to pump blood at an output sufficient enough to meet the
metabolic demands of the entire body.1 It should be noted that there are many different
subtypes of heart failure but the common thread is the profound decrease in cardiac
output. More specifically, ventricular remodeling and neurohormonal activation of the
sympathetic nervous system as well as the renin-angiotensin-aldosterone system are
enormous players in the pathophysiology of heart failure.1 This pathophysiology leaves
the patient with symptoms of fatigue, orthopnea, a chronic non-productive cough,
peripheral edema, and dyspnea on exertion or at rest, depending on severity. All
symptoms are the result of hypervolemia; an environment primarily created by the
neurohormones from the kidneys that increase retention of water and sodium.1 Fluid
regulation, therefore, is the primary target of heart failure treatment.1 This paper focuses
on three randomized controlled trials (RCTs) that evaluated the overall efficacy of
ultrafiltration as primary treatment for congestive heart failure and its ability to decrease
recidivism as well as cost by decreasing hospital stay.
Congestive heart failure is of major relevance to the Physician Assistant practice
because it is a wide and growing diagnosis. 5.8 million people in the U.S. have heart
failure with approximately 10 per 1000 people being diagnosed after 65 years of age.2 1
in 5 patients die within the first year of diagnosis.2 Ultrafiltration has the potential to offer
patients decreased hospital stays, less recidivism, and longer lifespan.2 Heart failure is the
leading cause of hospitalization in patients > 65 years of age and 65% are re-hospitalized
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in a one-year period. In addition, the most common causes of heart failure are three of
the most common disease processes that Physician Assistants in any field of medicine
may encounter in their careers: Coronary Artery Disease, Hypertension and Diabetes. In
2010, heart failure was estimated to cost $39.2 billion.2 The estimated 3.4 outpatient
visits per heart failure patient per year contribute to the extensive cost.2
Approximately 90% of the annual hospitalizations for heart failure are the result
of patients suffering the symptoms of volume overload.3 Current treatment
recommendations are aimed towards achieving euvolemia, most commonly treated with
intravenous diuretics.3 More and more hospitals, however, are trying ultrafiltration due to
the prevalence of diuretic resistance and post-diuretic sodium retention. Post-diuretic
sodium retention results in inadequate diuresis and the return of hypervolemia
symptoms.3
An overwhelming 88% of patients are treated with intravenous diuretics and
sodium restriction from diet.4 While intravenous diuretics can be effective for congestive
heart failure, ultrafiltration is being proposed as primary treatment here because fluid
removal by this process can improve cardiac output and renal perfusion without altering
glomerular filtration rate, NaCl uptake in the kidneys or renin secretion as intravenous
diuretics tend to do.3 Ultrafiltration is also being proposed as primary treatment because
heart failure patients may require less hospitalization time over the course of their
disease.
Objective:
The objective of this review is to determine if ultrafiltration can, in fact, be an
effective alternative as primary treatment for congestive heart failure patients. Previously
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studied randomized controlled trials have suggested that ultrafiltration can produce
greater fluid loss and maintain this fluid loss at 90 days from the time of treatment,
thereby decreasing recidivism.5
Methods:
All three randomized controlled trials utilized for this review were selected
because their population group included hospitalized heart failure patients greater than 18
years of age. The interventions used for these heart failure patients was ultrafiltration and
the comparison group was heart failure patients treated with intravenous loop diuretics
such as 20mg Furosemide, 10mg Torsemide, and 1mg Bumetanide.
Information obtained for this review was found using both Ovid Medline and
PubMed databases. Inclusion criteria included randomized controlled trials limited to the
English language and published data. The keywords used were “Heart Failure”, “CHF”,
and “Ultrafiltration”. Further inclusion criteria was based on relevance and whether or
not the outcomes evaluated in the studies dealt with POEMS (patient oriented evidence
that matters). Exclusion criteria included DOEMs (disease oriented evidence that
matters) and studies that were not previously used in any systematic review or metaanalysis found on the Cochrane Database. Studies were not excluded based on lack of
statistical significance. Ultimately, three studies were found and analyzed and they
included: 1) a randomized, non-blinded, multicenter controlled trial comparing
ultrafiltration to intravenous diuretics in patients hospitalized with heart failure, 2) a
randomized, non-blinded controlled trial comparing the renal effects of ultrafiltration to
those of intravenous furosemide, and 3) a randomized, non-blinded controlled trial

Tallis; CHF & Ultrafiltration 4
comparing ultrafiltration to “usual care” consisting of intravenous furosemide and
intravenous inotropes.
Outcomes measured in all three trials dealt with patient oriented evidence that
mattered to the patients. For example, in all three studies, weight loss was measured after
48 hours, at discharge, and at 10, 30 and 90 days post-discharge for both the
ultrafiltration and the intravenous diuretic groups. Dyspnea was also noted after 48 hours
and measured as a perception of the patient on a scale from 1 to 7; 1 being markedly
worse.5 In addition, a 6-minute walk distance was performed to also measure dyspnea.
The ultrafiltrate removed was measured right at the patient’s bedside. This value was
recorded as net fluid loss after 48 hours. For the intravenous diuretic and usual care
groups, this value was recorded as urine output. The final outcome measured that
mattered to patients was the number of re-hospitalizations within a 90-day period for
heart failure related issues.5
Results:
Major demographics and characteristics of the studies utilized for this review are
displayed in Table 1. It can be noted that all three studies had very similar inclusion
criteria, including: 2+ pitting lower extremity edema, jugular venous distention, ascites,
pulmonary edema or pleural effusion, and

2-pillow orthopnea. All patients were older

than 18 and being hospitalized for congestive heart failure at the time of the study.
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Table 1 – Demographics & Characteristics of included studies:
Characteristics of studies included in Systematic Review of the effectiveness of Ultrafiltration as
primary treatment for Congestive Heart Failure.
W/D
Study
Type #Pts Age Inclusion
Exclusion
Interventions
(yrs)
Criteria
Criteria
Bart et al., RCT 40
> 18 2+ edema of
Severe stenotic
2
Pts randomized to
2005
LE at least
valvular disease,
receive Ultrafiltration
one of the
ACS, Systolic
x 24-48hrs +/following:
BP < 90mmHg,
1. ACE-Is/ARBs
elevated JVD, HCT > 40%,
2. B-Blockers
pulm edema,
poor peripheral
3. Digoxin
pleural
venous acces
4. Nesiritide
effusion,
Hemodyn
ascites
instability
Constanzo, RCT 200 > 18 Age > 18 & at ACS
20
Pts randomized to
et al., 2007
least 2 of the
Unattainable
receive Ultrafiltration
following:
venous access
x 48 hrs
2+ peripheral Systolic BP < 90
edema;
mmHg
JVD > 7 cm;
Serum
Ascites;
Creatinine > 3
Pulm edema
HCT > 45%
or pleural
Vasoactive drug
effusion;
use
Rales or PND Systemic
infection
Heart transplant
Rogers, et
RCT 26
> 18 Age > 18
ACS
5
Pts randomized to
al., 2008
EF < 40%
Systolic BP <
receive Ultrafiltration
> 2+ pitting
90mmHg
x 48 hrs +/- *
edema of LE
Serum creatinine
1. ACE-Is/ARBs
JVP > 10 cm
> 3 mg/dL
2. B-Blockers
Ascites
HCT > 45%
3. Spironolactone
PND
Unattainable
4. Digoxin
*only used if pts were on
> 2 pillow
venous access
these meds prior to
orthopnea
Clinical
hospitalization
Pulm edema
instability likely
or Pleural
to require
effusion
nitrprusside.
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Table 2 outlines the main endpoints measured in the Costanzo 2007 study which
compared ultrafiltration (UF) to intravenous diuretics (IVD) for symptom management
and number of rehospitalizations for congestive heart failure symptoms. Weight loss,
dyspnea and rate of recidivism are all endpoints that are both extremely important and
evident to patients. One of the primary objectives of the study was to show that in
hypervolemic patients hospitalized with congestive heart failure, ultrafiltration can
produce greater weight loss over a given period of time versus intravenous diuretics. At
48 hours, weight loss was greater in the ultrafiltration group than in the intravenous
diuretic group with a statistically significant p-value of 0.001, evaluated with the
Wilcoxon’s rank sum test.5
Dyspnea scores rated by patients on a scale of 1 through 7, 1 being markedly
worse and 7 being markedly better, proved similar between the UF and IVD groups, with
the mean dyspnea scores being 5.4 and 5.2 respectively leaving a p-value lacking
statistical significance (0.588). Finally, at 90 days post-discharge, the UF group had 16
of 89 patients rehospitalized (18%) versus the IVD group with 28 of 87 being
rehospitalized (32%) for CHF-related symptoms, giving a p-value approaching statistical
significance at 0.037%, calculated with the Kaplan-Meier analysis. Although the relative
risk reduction or relative benefit increases could not be calculated here for weight loss or
dyspnea, we were able to see a 20.6% relative benefit increase for UF patients calculated
based on the number of patients in the study that were not rehospitalized for CHF-related
symptoms. 5
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Table 2. Comparison of weight loss and dyspnea scores in pts after 48 hours and 8 hours
respectively between UF and IV Diuretics and how volume reduction affects recidivism.
Costanzo 2007
Mean weight loss and dyspnea scores evaluated by Wilcoxon rank sum test and the
beneficial effects of UF v IVD on rehospitalization.

Weight (kg)

*Dyspnea Score
(1-7)

Hospitalizations
for CHF

Baseline
UFa
101 27

Baseline
IVDb
96 29

Baseline
UF

Baseline
IVD

3-7

1-7

UF
Wt Loss
5.0 3.1

UF

5.4

Baseline
Pre-UF

Baseline 90 days
Pre-IVD post -

1.6 1.9

1.5

UF

1.7 18%

IVD
Wt Loss
3.1 3.5

IVD

1.1

5.2

90 days
post IVD

P-

32%

0.037

P-value
0.001

P-value

1.2

0.588

RBIc

ABI

NNT

20.6%

14%

8

value

* Dyspnea scores were measured from 1 through 7; 1 being markedly worse and 7 being
markedly better
a
UF – Ultrafiltration
b
IVD – Intravenous Diuretics
c
RBI, ABI & NNT values were calculated based on “# of CHF patients not rehospitalized
for CHF symptoms”.

In Table 3 we see the effect of UF and IVD on fluid loss after 48 hours as
reported in the Rogers 2008 study. This study pointed out that some patients may have
diuretic resistance and this could account for the difference in renal function and
subsequently fluid removal in the Furosemide group versus UF. All continuous variables
in this study were reported as mean

standard deviation. The group comparisons were
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made using a paired t-test (2-tailed) and differences between the treatment groups
evaluated with the Fisher exact test. For net fluid removal at 48 hours, which included
urine output plus ultrafiltrate for the UF group, p = 0.682 and for weight loss p = 0.85 as
the numbers between the UF and Furosemide groups were very similar, and therefore, not
statistically significant.3
Table 3. Effect of UF and IVD on Fluid Loss after 48 hours
Rogers 2008
Fluid Loss and subsequent weight loss of CHF patients given IV Furosemide vs UF

*Net Fluid
Loss

UF
5864 2414

UF
Weight Loss

2.2

2.6

IVDa
5786 2587

P-valueb
0.682

IVD

P-value

1.9

2.7

0.850

*Net Fluid loss was measured in mL as total urine output after 48 hrs for IVD group and
as ultrafiltrate plus urine output for the UF group.
a
Furosemide dose over 48 hrs ranged from 240-520mg
b
P-values: Unpaired t-test was used for comparisons between treatment groups and
differences were evaluated with the Fisher exact test. RRR, ARR, and NNT values could
not be calculated due to having only continuous data.
Table 4 shows results from Bart 2005. Although this study was ultimately
measuring weight loss, the p-value ended up not being statistically significant (0.240).
UF proved more favorable, however, for reduction of dyspnea (p = 0.039) and global
CHF symptoms (p= 0.023) suggesting that fluid removal may be more effective with UF
vs. usual care methods such as IV diuretics and inotropes.4 In addition, 56.3% of UF
patients reported “marked improvement” in global CHF symptoms versus 18.8% in the
usual care group, and 31.3% of those treated wth UF reported “marked improvement”
with dyspnea compared to 18.8% of those treated with usual care.4
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Table 4. Symptom reduction comparisons in CHF patients treated with UF and “usual
care”
Bart 2005
Percent of persons who reported improvements or no change in CHF symptoms,
specifically dyspnea, after 48 hours of treatment.
Global CHF
UF
Sx
Marked
56.3%
Improvement
No Change
6.3%

UCa
18.8%

P-valueb

RBI

ABI

NNT

0.023

18.1%

10.5%

10

18.8%

Dyspnea Sx

UF

UC

P-value

RBI

ABI

NNT

Marked
Improvement

31.3%

12.5%

0.039

55.5%

26.3%

4

No Change

6.3%

37.5%

a

– UC = Usual Care group was treated primarily with IV diuretics, but IV inotropes were
also used in several patients.
b
– P-values: Two-sided Wilcoxon rank sum test was used since this data was continuous.
Table 5 shows adverse events and NNH values. Only two of the three trials used
included information about adverse events along with their data. Common to both studies
was infection related to catheter site and occurred in 1 of 19 patients in the Bart 2005
study and in 1 of 89 in the Costanzo 2007 study; both events were minor and did not
exclude that person from the study.4,5 Catheter-related infection was the only adverse
event reported in the 2005 study. Hypotension was the most commonly reported adverse
event in Costanzo 2007, though no one dropped out of the study or was excluded
because of it. Other adverse events reported in the 2007 study were worsening heart
failure, cardiac arrest, arrhythmias, and anemia, but it is impossible to pinpoint UF or
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IVD as the causative factor of these events, especially taking into consideration the
baseline health status of the patients enrolled in the clinical trial.5
Table 5. *Adverse Events
Costanzo 2007
N=89 (UF), N= 87 (IVD)

Bart 2005
N=19 (UF), N=19 (Usual Care)

UF
1 (1%)

IVD
0

Hypotension

22 (25%)

10 (11%)

Arrhythmias

10 (11%)

6 (7%)

Cardiac arrest

4 (4%)

6 (7%)

NNH

8
Hypotension

-

Infection (catheter-

UF
1 (5%)

UC
0

19
Infection

-

related)

Catheter-related

*Adverse events were not reported in Rogers 2008 study
- events not reported in study
Discussion:
Ultrafiltration is a non-drug based treatment option for congestive heart failure
that can remove up to 1 lb per hour of excess volume from the blood. It can be compared
to dialysis in that blood is moved extracorporeally, filtered of only sodium and water, and
then returned to the body. The volume of blood cycled is, however, much less compared
to hemodialysis leading to less incidence of hemodynamic instability. 88% of heart
failure patients are currently being treated with intravenous diuretics but many patients
develop diuretic resistance.4 It is for these patients that ultrafiltration is currently being
utilized most. The machine attached peripherally to the patient filters the blood through a
semipermeable membrane by way of a pressure gradient system. The rate at which fluid
is removed through the semipermeable membrane can be selected based on the patients’
hemodynamic conditions. If patients become hypotensive, which did occur in the
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Costanzo 2007 trial, it is possible to slow the rate of blood flow or ultrafiltration to avoid
hemodynamic instability.6
While the costs of ultrafiltration exceed those of intravenous diuretics inititally,
the thought is that reduction in length of hospital stays and decreased rates of recidivism
will actually even out the cost discrepancy between the two treatment modalities.
Monetary information, though very relevant, was not mentioned in any of the three RCTs
studied.
All RCTs effectively demonstrated that in heart failure patients with volume
overload, ultrafiltration results in greater fluid removal and is not associated with harmful
adverse events. The most obvious limitations to all RCTs studied were the very small
sample sizes. Furthermore, a more defined sample population needs to be studied to
accurately determine rate of rehospitalization. The admission criteria utilized for these
RCTs was very broad. Hospital readmission rates, for example, might be less favorable if
the population studied were restricted to only class IV heart failure patients.
Conclusion:
While ultrafiltration has proven to be a safe alternative to intravenous diuretics for
the treatment of heart failure, there is not enough consistent, significant data to say that it
can be used as primary treatment. Further studies with a larger, yet more refined sample
populations should be included. The age requirement should be 65 and older to better
reflect the core heart failure population. Studies should further split intervention groups
into the NYHA classes of heart failure III and IV. These changes will aid in proving true
long-term efficacy and cost-effectiveness.
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